window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 19, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

SpliSense

  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Cystic Fibrosis Foundation backs SpliSense with up to $13m to advance SPL84 Phase 2b study

    spliesense-cystic-fibrosis-foundation-spl84-phase2b SpliSense has secured up to $13 million in funding [...]

    June 16, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Mabion revives MabionCD20 through rare disease collaboration with Oddifact
    Categories: Biotech & Pharma Business, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Innovative Molecules adds Epstein-Barr virus antiviral programme to pipeline
    Categories: Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Poolbeg secures European patent decision for POLB 001 in cytokine release syndrome
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top